Zhejiang Cancer Hospital
🇨🇳China
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04790409
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT04691388
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Anlotinib to Malignant Brainstem Glioma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04668508
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Anterior Quadratus Lumborum Block at the Lateral Supra-arcuate Ligament for Analgesia After Open Liver Surgery
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT04668391
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04665986
Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04663763
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04657848
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04560751
A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04543890
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04512417
- Locations
- 🇨🇳
Zhejiang Province Cancer Hospital, Hanzhou, Zhejiang, China
© Copyright 2024. All Rights Reserved by MedPath